Paracetamol (acetaminophen) for chronic non-cancer pain in children and adolescents

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 2, 2017, Pages

  Cooper, Tess E ^a   Fisher, Emma ^b   Anderson, Brian ^c   Wilkinson, Nick M R ^d   Williams, David Glyn ^e   Eccleston, Christopher ^a,f  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b Child Health Institute   (United States)

^c STARSHIP CHILDREN S HOSPITAL   (New Zealand)

^d EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PARACETAMOL; PLACEBO; ANALGESIC AGENT;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADOLESCENT; ADVERSE OUTCOME; ANALGESIA; ARTICLE; CHILD; CHRONIC PAIN; COLOR ANALOG SCALE; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; FACES PAIN SCALE; FLUSHING; HUMAN; HYPOTENSION; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE; LEUKOPENIA; LIVER FAILURE; MALAISE; NEUTROPENIA; NUMERIC RATING SCALE; PAIN ASSESSMENT; PAIN INTENSITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TACHYCARDIA; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ACETAMINOPHEN; ADOLESCENT; ANALGESICS, NON-NARCOTIC; CHILD; CHRONIC PAIN; HUMANS;

EID: 85027718400     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD012539     Document Type: Article

References (59)

1. American Medical Association. Paediatric pain management. Pain managementwww.ama-cmeonline.com/pain_mgmt/printversion/ama_painmgmt_m6.pdf (accessed 25 January 2016) 2013.
2. Cochrane Pain, Palliative and Supportive Care Group. PaPaS author and referee guidance. papas.cochrane.org/papas-documents (accessed 16 July 2016) 2012.
3. Joint Formulary Committee. British National Formulary. London (UK): BMJ Group and Pharmaceutical Press, 2016.
4. Botting R, Ayoub SS. COX-3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins, Leukotrienes and Essential Fatty Acids 2005;72:85-7.
5. Caes L, Boemer KE, Chambers CT, Campbell-Yeo M, Stinson J, Birnie KA, et al. A comprehensive categorical and bibliometric analysis of published research articles on pediatric pain from 1975 to 2010. Pain 2016;157(2):302-13. [DOI: 10.1097/j.pain.0000000000000403]
6. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, et al. Nonsteroidal anti inflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113:1578-87.
7. Cooper TE, Fisher E, Gray A, Krane E, Sethna NF, van Tilburg M, et al. Opioids for chronic non-cancer pain in children and adolescents. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.CD012538]
8. Cooper TE, Heathcote L, Clinch J, Gold J, Howard R, Lord S, et al. Antidepressants for chronic non-cancer pain in children and adolescents. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.CD012535]
9. Cooper TE, Heathcote L, Anderson B, Gregoire MC, Ljungman G, Eccleston C. Non-steroidal anti-inflammatory drugs (NSAIDs) for cancer-related pain in children and adolescents. Cochrane Database of Systematic Reviews 2017, Issue In press.
10. Daly FFS, Fountain JS, Murray L, Graudins A, Buckley NA. Guidelines for the management of paracetamol poisoning in Australia and New Zealand--explanation and elaboration. A consensus statement from clinical toxicologists consulting to the Australasian poisons information centres. Medical Journal of Australia 2008;188:296-301.
11. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005]
12. Eccleston C, Malleson PM. Management of chronic pain in children and adolescents (Editorial). BMJ 2003;326:1408-9.
13. Eccleston C, Cooper TE, Fisher E, Anderson B, Wilkinson N. Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.CD012537]
14. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005;46:500-7.
15. Forrest JA, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clinical Pharmacokinetics 1982;7(2):93-107. [PUBMED: 7039926]
16. Graham GG, Davies MJ, Day RO, Mohamudally A, Scott KF. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology 2013;21:201-32.
17. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6. [DOI: 10.1136/bmj.39489.470347.AD]
18. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64:383-94. [DOI: 10.1016/j.jclinepi.2010.04.026]
19. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coelle P, et al. Making an overall rating of the confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66(2):151-7. [DOI: 10.1016/j.jclinepi.2012.01.006]
20. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158-72. [DOI: 10.1016/j.jclinepi.2012.01.012]
21. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Available from www.cochrane-handbook.org. The Cochrane Collaboration.
22. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB Journal 2008;22:383-90.
23. Hinz B, Brune K. Paracetamol and cyclooxygenase inhibition: is there a cause for concern?. Annals of the Rheumatic Diseases 2012;71:20-5.
24. Hoffman DL, Sadosky A, Dukes EM, Alvir J. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?. Pain 2010;149(2):194-201. [DOI: 10.1016/j.pain.2009.09.017]
25. Jozwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Poloniae Pharmaceutica 2014;71:11-23.
26. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107:224-33.
27. McQuay H, Moore R. An Evidence-based Resource for Pain Relief. Oxford (UK): Oxford University Press, 1998.
28. Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097.
29. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle (WA): IASP Press, 2008:15-24. [ISBN: 978-0-931092-69-5]
30. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2]
31. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]
32. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360-4.
33. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374-9. [DOI: 10.1136/ard.2009.107805]
34. Moore RA, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Numbers-needed-to-treat analyses--do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials. Pain 2010;151(3):592-7. [DOI: 10.1016/j.pain.2010.07.2013]
35. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982-9. [DOI: 10.1016/j.pain.2010.11.030]
36. Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427-32. [DOI: 10.1097/EJA.0b013e328343c569]
37. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.004]
38. Moore RA, Straube S, Aldington D. Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400-12. [DOI: 10.1111/anae.12148]
39. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690. [DOI: 10.1136/bmj.f2690]
40. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice 2014;14(1):79-94.
41. Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions--individual patient data responder analysis. European Journal of Pain 2014;18(1):67-75. [DOI: 10.1002/j.1532-2149.2013.00341.x]
42. National Institute for Health and Care Excellence. Analgesia - mild-to-moderate pain. cks.nice.org.uk/analgesia-mild-to-moderate-pain#!scenario:1 (accessed March 2016) 2016.
43. O'Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchinson JW, et al. Patient-centered perspective on treatment outcomes in chronic pain. Pain Medicine 2010;11(1):6-15. [DOI: 10.1111/j.1526-4637.2009.00685.x]
44. McGrath PJ, Walco GA, Turk DC, Dworking RH, Brown MT, Davidson K, et al. Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT. Journal of Pain 2008;9(9):771-83.
45. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
46. Ripamonti C, Bandieri E. Pain therapy. Oncology/Hematology 2008;70:145-59. [DOI: 10.1016/j.critrevonc.2008.12.005]
47. Roberts E, Delgado Nunes V, Buckner S, Latchem S, Constanti M, Miller P, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Annals of Rheumatic Diseases 2016;75(3):552-9.
48. Sheen CL, Dillon JF, Bateman DN, Simpson KJ, Macdonald TM. Paracetamol toxicity: epidemiology, prevention and costs to the health-care system. QJM 2002;95:609-19.
49. Stinson JN, Kavanagh T, Yamada J, Gill N, Stevens B. Systematic review of the psychometric properties, interpretability and feasibility of self-report pain intensity measures for use in clinical trials in children and adolescents. Pain 2006;125(1-2):143-57. [DOI: 10.1016/j.pain.2006.05.006]
50. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrolment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology 2008;66(2):266-75. [DOI: 10.1111/j.1365-2125.2008.03200.x]
51. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia--responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. [DOI: 10.1186/1471-2474-11-150]
52. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29. [DOI: 10.1186/1471-2377-8-29]
53. United Nations. World population prospects 2015 - population indicators. esa.un.org/unpd/wpp/Download/Standard/Population/ (accessed 29 February 2016) 2015.
54. von Baeyer CL, Spagrud LJ. Systematic review of observational (behavioural) measures of pain for children and adolescents aged 3 to 18 years. Pain 2007;127(1-2):140-50. [DOI: 10.1016/j.pain.2006.08.014]
55. WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses. WHO Press, World Health Organization 2012. [ISBN 978 92 4 154812 0]
56. Wiffen PJ, Cooper TE, Anderson AK, Gray A, Gregoire MC, Ljungman G, et al. Opioids for cancer-related pain in children and adolescents. Cochrane Database of Systematic Reviews 2017, Issue In press.
57. Wiffen PJ, Cooper TE, Heathcote L, Clinch J, Howard R, Krane E, et al. Antiepileptic drugs for chronic non-cancer pain in children and adolescents. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.CD012536]
58. World Bank. Data - population ages 0-14 (% of total). data.worldbank.org/indicator/SP.POP.0014.TO.ZS (accessed 29 February 2016) 2014.
59. Zyoud SH, Al-Jabi SW, Sweileh WM. Worldwide research productivity of paracetamol (acetaminophen) poisoning: a bibliometric analysis (2003-2012). Human and Experimental Toxicology 2015;34(1):12-23. [DOI: 10.1177/0960327114531993]